



GIC Becomes Minority Investor in Cimed

March 17, 2025 – Cimed announces today that it has concluded negotiations for the entry of GIC, Singapore's Sovereign Wealth Fund, as a minority shareholder of the company.

The partnership strengthens Cimed's leadership and accelerates its mission to provide health and well-being to all Brazilians.

The entry of GIC is part of the Company's growth strategy called "Cimed's New Era" whose objective is to triple the company's revenue over the next five years through innovation, technology, new business opportunities, and inorganic moves.

"We are proud to have a strategic partner with global connections like GIC by our side to accelerate our growth journey," says **João Adibe Marques, CEO of Cimed**.

"This move is a milestone in our 48-year history, a result of Cimed's reputation and growth potential," **João Adibe concludes**.

Cimed was advised in this process by J.P. Morgan and Spinelli Advogados.

Cimed reinforces its confidence and commitment to Brazil.

<END>

About GIC

GIC is a leading global investment firm established in 1981 to secure Singapore's financial future. As the manager of Singapore's foreign reserves, GIC takes a long-term, disciplined approach to investing and is uniquely positioned across a wide range of asset classes and active strategies globally. These include equities, fixed income, real estate, private equity, venture capital, and infrastructure. Its long-term approach, multi-asset capabilities, and global connectivity enable it to be an investor of choice. GIC seeks to add meaningful value to its investments. Headquartered in Singapore, GIC has a global talent force of over 2,300 people in 11 key financial cities and has investments in over 40 countries. For more information, please visit www.gic.com.sg or follow on LinkedIn.

About Cimed

Cimed is the third-largest pharmaceutical company in Brazil by sales volume, with 48 years of history. Known by 72% of Brazilians, the Cimed brand is present in 6 out of every 10 households in the country and has the highest awareness among Generation Z in the pharmaceutical sector. Cimed serves Brazilians through all stages of life with its market-leading brands, such as Cimed Genéricos, Lavitan, Carmed, Cimegripe, Kmed, Xô Inseto, among others. Additionally, it is expanding strongly into new markets and categories, such as baby care products with the João e Maria brand, oral care with Carmed, and aesthetics with the Milimetric brand. Cimed has a national distribution network, directly serving more than 60,000 points of sale and reaching 90% of Brazilian pharmacies. For more information, visit www.cimedremedios.com.br or follow on LinkedIn.